getVariantMetadata.RdRetrieve metadata information for a specific variant from the CIViC DB
getVariantMetadata(id, type)
| id | Internal CIViC ID of the variant of interest |
|---|---|
| type | Type of metadata (comments, suggested_changes, revisions, evidence_items) |
An S3 Object of type civic_api containing the content, url, and response
getVariantMetadata(id = 1, type = "comments")#> $content #> list() #> #> $url #> [1] "https://civicdb.org/api/variants/1/comments" #> #> $response #> Response [https://civicdb.org/api/variants/1/comments] #> Date: 2019-09-03 16:44 #> Status: 200 #> Content-Type: application/json; charset=utf-8 #> Size: 2 B #> #> #> attr(,"class") #> [1] "civic_api"getVariantMetadata(id = 1, type = "revisions")#> $content #> $content[[1]] #> $content[[1]]$id #> [1] 64 #> #> $content[[1]]$action #> [1] "create" #> #> $content[[1]]$user #> $content[[1]]$user$username #> [1] "Admin" #> #> #> $content[[1]]$created_at #> [1] "2015-06-21T16:49:35.200Z" #> #> $content[[1]]$changes #> $content[[1]]$changes$gene_id #> [1] 4 #> #> $content[[1]]$changes$name #> [1] "BCR-ABL" #> #> $content[[1]]$changes$description #> [1] "The BCR-ABL fusion protein, commonly referred to as the philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML), but despite its ability initiate disease in mice, its status an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response." #> #> $content[[1]]$changes$deleted #> [1] FALSE #> #> $content[[1]]$changes$deleted_at #> NULL #> #> $content[[1]]$changes$genome_build #> NULL #> #> $content[[1]]$changes$chromosome #> NULL #> #> $content[[1]]$changes$start #> NULL #> #> $content[[1]]$changes$stop #> NULL #> #> $content[[1]]$changes$reference_bases #> NULL #> #> $content[[1]]$changes$variant_bases #> NULL #> #> $content[[1]]$changes$representative_transcript #> NULL #> #> $content[[1]]$changes$chromosome2 #> NULL #> #> $content[[1]]$changes$start2 #> NULL #> #> $content[[1]]$changes$stop2 #> NULL #> #> #> $content[[1]]$diffs #> $content[[1]]$diffs$gene #> $content[[1]]$diffs$gene$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>ABL1</ins></li>\n </ul>\n</div>\n" #> #> $content[[1]]$diffs$gene$final #> [1] "ABL1" #> #> #> $content[[1]]$diffs$name #> $content[[1]]$diffs$name$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>BCR-ABL</ins></li>\n </ul>\n</div>\n" #> #> $content[[1]]$diffs$name$final #> [1] "BCR-ABL" #> #> #> $content[[1]]$diffs$description #> $content[[1]]$diffs$description$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>The BCR-ABL fusion protein, commonly referred to as the philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML), but despite its ability initiate disease in mice, its status an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response.</ins></li>\n </ul>\n</div>\n" #> #> $content[[1]]$diffs$description$final #> [1] "The BCR-ABL fusion protein, commonly referred to as the philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML), but despite its ability initiate disease in mice, its status an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response." #> #> #> $content[[1]]$diffs$deleted #> $content[[1]]$diffs$deleted$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>false</ins></li>\n </ul>\n</div>\n" #> #> $content[[1]]$diffs$deleted$final #> [1] FALSE #> #> #> $content[[1]]$diffs$deleted_at #> $content[[1]]$diffs$deleted_at$diff #> [1] "<div class=\"diff\"></div>" #> #> $content[[1]]$diffs$deleted_at$final #> NULL #> #> #> $content[[1]]$diffs$genome_build #> $content[[1]]$diffs$genome_build$diff #> [1] "<div class=\"diff\"></div>" #> #> $content[[1]]$diffs$genome_build$final #> NULL #> #> #> $content[[1]]$diffs$chromosome #> $content[[1]]$diffs$chromosome$diff #> [1] "<div class=\"diff\"></div>" #> #> $content[[1]]$diffs$chromosome$final #> NULL #> #> #> $content[[1]]$diffs$start #> $content[[1]]$diffs$start$diff #> [1] "<div class=\"diff\"></div>" #> #> $content[[1]]$diffs$start$final #> NULL #> #> #> $content[[1]]$diffs$stop #> $content[[1]]$diffs$stop$diff #> [1] "<div class=\"diff\"></div>" #> #> $content[[1]]$diffs$stop$final #> NULL #> #> #> $content[[1]]$diffs$reference_bases #> $content[[1]]$diffs$reference_bases$diff #> [1] "<div class=\"diff\"></div>" #> #> $content[[1]]$diffs$reference_bases$final #> NULL #> #> #> $content[[1]]$diffs$variant_bases #> $content[[1]]$diffs$variant_bases$diff #> [1] "<div class=\"diff\"></div>" #> #> $content[[1]]$diffs$variant_bases$final #> NULL #> #> #> $content[[1]]$diffs$representative_transcript #> $content[[1]]$diffs$representative_transcript$diff #> [1] "<div class=\"diff\"></div>" #> #> $content[[1]]$diffs$representative_transcript$final #> NULL #> #> #> $content[[1]]$diffs$chromosome2 #> $content[[1]]$diffs$chromosome2$diff #> [1] "<div class=\"diff\"></div>" #> #> $content[[1]]$diffs$chromosome2$final #> NULL #> #> #> $content[[1]]$diffs$start2 #> $content[[1]]$diffs$start2$diff #> [1] "<div class=\"diff\"></div>" #> #> $content[[1]]$diffs$start2$final #> NULL #> #> #> $content[[1]]$diffs$stop2 #> $content[[1]]$diffs$stop2$diff #> [1] "<div class=\"diff\"></div>" #> #> $content[[1]]$diffs$stop2$final #> NULL #> #> #> #> #> $content[[2]] #> $content[[2]]$id #> [1] 779 #> #> $content[[2]]$action #> [1] "update" #> #> $content[[2]]$user #> $content[[2]]$user$id #> [1] 23 #> #> $content[[2]]$user$name #> [1] "Rachel Bilski" #> #> $content[[2]]$user$last_seen_at #> [1] "2017-01-05T19:07:12.931Z" #> #> $content[[2]]$user$username #> [1] "rbilski" #> #> $content[[2]]$user$role #> [1] "curator" #> #> $content[[2]]$user$avatar_url #> [1] "https://secure.gravatar.com/avatar/d41d8cd98f00b204e9800998ecf8427e.png?d=identicon&r=pg&s=32" #> #> $content[[2]]$user$avatars #> $content[[2]]$user$avatars$x128 #> [1] "https://secure.gravatar.com/avatar/5ac236988c317dd394f64d83eb8618f2.png?d=identicon&r=pg&s=128" #> #> $content[[2]]$user$avatars$x64 #> [1] "https://secure.gravatar.com/avatar/5ac236988c317dd394f64d83eb8618f2.png?d=identicon&r=pg&s=64" #> #> $content[[2]]$user$avatars$x32 #> [1] "https://secure.gravatar.com/avatar/5ac236988c317dd394f64d83eb8618f2.png?d=identicon&r=pg&s=32" #> #> $content[[2]]$user$avatars$x14 #> [1] "https://secure.gravatar.com/avatar/5ac236988c317dd394f64d83eb8618f2.png?d=identicon&r=pg&s=14" #> #> #> $content[[2]]$user$area_of_expertise #> NULL #> #> $content[[2]]$user$orcid #> [1] "" #> #> $content[[2]]$user$display_name #> [1] "rbilski" #> #> $content[[2]]$user$created_at #> [1] "2015-03-18T20:18:44.139Z" #> #> $content[[2]]$user$url #> [1] "" #> #> $content[[2]]$user$twitter_handle #> [1] "" #> #> $content[[2]]$user$facebook_profile #> [1] "" #> #> $content[[2]]$user$linkedin_profile #> [1] "" #> #> $content[[2]]$user$bio #> [1] "" #> #> $content[[2]]$user$country #> $content[[2]]$user$country$id #> [1] 214 #> #> $content[[2]]$user$country$iso #> [1] "US" #> #> $content[[2]]$user$country$name #> [1] "United States" #> #> #> $content[[2]]$user$featured_expert #> [1] FALSE #> #> $content[[2]]$user$accepted_license #> NULL #> #> $content[[2]]$user$signup_complete #> NULL #> #> $content[[2]]$user$affiliation #> [1] "" #> #> $content[[2]]$user$organization #> named list() #> #> #> $content[[2]]$created_at #> [1] "2015-07-07T22:38:53.938Z" #> #> $content[[2]]$changes #> $content[[2]]$changes$description #> $content[[2]]$changes$description[[1]] #> [1] "The BCR-ABL fusion protein, commonly referred to as the philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML), but despite its ability initiate disease in mice, its status an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response." #> #> $content[[2]]$changes$description[[2]] #> [1] "The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). But despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response." #> #> #> #> $content[[2]]$diffs #> $content[[2]]$diffs$description #> $content[[2]]$diffs$description$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"del\"><del>The BCR-ABL fusion protein, commonly referred to as the <strong>p</strong>hiladelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML)<strong>, b</strong>ut despite its ability initiate disease in mice, its status an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response.</del></li>\n <li class=\"ins\"><ins>The BCR-ABL fusion protein, commonly referred to as the <strong>P</strong>hiladelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML)<strong>. B</strong>ut despite its ability <strong>to </strong>initiate disease in mice, its status a<strong>s a</strong>n initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response.</ins></li>\n </ul>\n</div>\n" #> #> $content[[2]]$diffs$description$final #> [1] "The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). But despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response." #> #> #> #> #> $content[[3]] #> $content[[3]]$id #> [1] 957 #> #> $content[[3]]$action #> [1] "update" #> #> $content[[3]]$user #> $content[[3]]$user$username #> [1] "Admin" #> #> #> $content[[3]]$created_at #> [1] "2015-07-10T15:22:39.287Z" #> #> $content[[3]]$changes #> $content[[3]]$changes$reference_build #> $content[[3]]$changes$reference_build[[1]] #> NULL #> #> $content[[3]]$changes$reference_build[[2]] #> [1] 1 #> #> #> #> $content[[3]]$diffs #> $content[[3]]$diffs$reference_build #> $content[[3]]$diffs$reference_build$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>1</ins></li>\n </ul>\n</div>\n" #> #> $content[[3]]$diffs$reference_build$final #> [1] 1 #> #> #> #> #> $content[[4]] #> $content[[4]]$id #> [1] 2498 #> #> $content[[4]]$action #> [1] "update" #> #> $content[[4]]$user #> $content[[4]]$user$id #> [1] 41 #> #> $content[[4]]$user$name #> [1] "Nick Spies" #> #> $content[[4]]$user$last_seen_at #> [1] "2019-01-20T03:51:36.969Z" #> #> $content[[4]]$user$username #> [1] "NickSpies" #> #> $content[[4]]$user$role #> [1] "admin" #> #> $content[[4]]$user$avatar_url #> [1] "https://secure.gravatar.com/avatar/3376aeb8439c5ab3e5d72fa2eeed39e5.png?d=identicon&r=pg&s=32" #> #> $content[[4]]$user$avatars #> $content[[4]]$user$avatars$x128 #> [1] "https://secure.gravatar.com/avatar/3376aeb8439c5ab3e5d72fa2eeed39e5.png?d=identicon&r=pg&s=128" #> #> $content[[4]]$user$avatars$x64 #> [1] "https://secure.gravatar.com/avatar/3376aeb8439c5ab3e5d72fa2eeed39e5.png?d=identicon&r=pg&s=64" #> #> $content[[4]]$user$avatars$x32 #> [1] "https://secure.gravatar.com/avatar/3376aeb8439c5ab3e5d72fa2eeed39e5.png?d=identicon&r=pg&s=32" #> #> $content[[4]]$user$avatars$x14 #> [1] "https://secure.gravatar.com/avatar/3376aeb8439c5ab3e5d72fa2eeed39e5.png?d=identicon&r=pg&s=14" #> #> #> $content[[4]]$user$area_of_expertise #> [1] "Research Scientist" #> #> $content[[4]]$user$orcid #> [1] "" #> #> $content[[4]]$user$display_name #> [1] "NickSpies" #> #> $content[[4]]$user$created_at #> [1] "2015-06-12T18:13:16.508Z" #> #> $content[[4]]$user$url #> [1] "" #> #> $content[[4]]$user$twitter_handle #> [1] "@NickSpies13" #> #> $content[[4]]$user$facebook_profile #> [1] "" #> #> $content[[4]]$user$linkedin_profile #> [1] "" #> #> $content[[4]]$user$bio #> [1] "Nick Spies is a staff analyst at the McDonnell Genome Institute and an MD student at Washington University School of Medicine. He has made substantial contributions to the development of genome analysis tools and resources at the Genome Institute including the Drug-Gene Interaction Database. He is a founding member of the CIViC team, helping to define the CIViC data model, and a leading content curator and a feature development consultant." #> #> $content[[4]]$user$country #> $content[[4]]$user$country$id #> [1] 214 #> #> $content[[4]]$user$country$iso #> [1] "US" #> #> $content[[4]]$user$country$name #> [1] "United States" #> #> #> $content[[4]]$user$featured_expert #> [1] TRUE #> #> $content[[4]]$user$accepted_license #> NULL #> #> $content[[4]]$user$signup_complete #> NULL #> #> $content[[4]]$user$affiliation #> [1] "" #> #> $content[[4]]$user$organization #> $content[[4]]$user$organization$id #> [1] 1 #> #> $content[[4]]$user$organization$name #> [1] "The McDonnell Genome Institute" #> #> $content[[4]]$user$organization$url #> [1] "http://genome.wustl.edu/" #> #> $content[[4]]$user$organization$description #> [1] "The McDonnell Genome Institute (MGI) is a world leader in the fast-paced, constantly changing field of genomics. A truly unique institution, we are pushing the limits of academic research by creating, testing, and implementing new approaches to the study of biology with the goal of understanding human health and disease, as well as evolution and the biology of other organisms." #> #> $content[[4]]$user$organization$profile_image #> $content[[4]]$user$organization$profile_image$x256 #> [1] "/system/organizations/profile_images/000/000/001/x256/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[4]]$user$organization$profile_image$x128 #> [1] "/system/organizations/profile_images/000/000/001/x128/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[4]]$user$organization$profile_image$x64 #> [1] "/system/organizations/profile_images/000/000/001/x64/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[4]]$user$organization$profile_image$x32 #> [1] "/system/organizations/profile_images/000/000/001/x32/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[4]]$user$organization$profile_image$x14 #> [1] "/system/organizations/profile_images/000/000/001/x14/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> #> $content[[4]]$user$organization$parent #> named list() #> #> #> #> $content[[4]]$created_at #> [1] "2015-10-21T20:11:23.770Z" #> #> $content[[4]]$changes #> $content[[4]]$changes$description #> $content[[4]]$changes$description[[1]] #> [1] "The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). But despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response." #> #> $content[[4]]$changes$description[[2]] #> [1] "The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). But despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and ponatinib) have seen some success in delivering a tumor response." #> #> #> #> $content[[4]]$diffs #> $content[[4]]$diffs$description #> $content[[4]]$diffs$description$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"del\"><del>The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). But despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and <strong>nilo</strong>tinib) have seen some success in delivering a tumor response.</del></li>\n <li class=\"ins\"><ins>The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). But despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and <strong>pona</strong>tinib) have seen some success in delivering a tumor response.</ins></li>\n </ul>\n</div>\n" #> #> $content[[4]]$diffs$description$final #> [1] "The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). But despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and ponatinib) have seen some success in delivering a tumor response." #> #> #> #> #> $content[[5]] #> $content[[5]]$id #> [1] 2643 #> #> $content[[5]]$action #> [1] "update" #> #> $content[[5]]$user #> $content[[5]]$user$id #> [1] 15 #> #> $content[[5]]$user$name #> [1] "Malachi Griffith" #> #> $content[[5]]$user$last_seen_at #> [1] "2019-08-29T20:56:30.703Z" #> #> $content[[5]]$user$username #> [1] "MalachiGriffith" #> #> $content[[5]]$user$role #> [1] "admin" #> #> $content[[5]]$user$avatar_url #> [1] "https://secure.gravatar.com/avatar/a4d9fc3b05d58cf3d3ba51dc30bb61d6.png?d=identicon&r=pg&s=32" #> #> $content[[5]]$user$avatars #> $content[[5]]$user$avatars$x128 #> [1] "https://secure.gravatar.com/avatar/a4d9fc3b05d58cf3d3ba51dc30bb61d6.png?d=identicon&r=pg&s=128" #> #> $content[[5]]$user$avatars$x64 #> [1] "https://secure.gravatar.com/avatar/a4d9fc3b05d58cf3d3ba51dc30bb61d6.png?d=identicon&r=pg&s=64" #> #> $content[[5]]$user$avatars$x32 #> [1] "https://secure.gravatar.com/avatar/a4d9fc3b05d58cf3d3ba51dc30bb61d6.png?d=identicon&r=pg&s=32" #> #> $content[[5]]$user$avatars$x14 #> [1] "https://secure.gravatar.com/avatar/a4d9fc3b05d58cf3d3ba51dc30bb61d6.png?d=identicon&r=pg&s=14" #> #> #> $content[[5]]$user$area_of_expertise #> [1] "Research Scientist" #> #> $content[[5]]$user$orcid #> [1] "0000-0002-6388-446X" #> #> $content[[5]]$user$display_name #> [1] "MalachiGriffith" #> #> $content[[5]]$user$created_at #> [1] "2015-02-26T22:25:34.692Z" #> #> $content[[5]]$user$url #> [1] "http://genome.wustl.edu/people/individual/malachi-griffith/" #> #> $content[[5]]$user$twitter_handle #> [1] "malachigriffith" #> #> $content[[5]]$user$facebook_profile #> [1] "" #> #> $content[[5]]$user$linkedin_profile #> [1] "malachigriffith" #> #> $content[[5]]$user$bio #> [1] "Dr. Griffith is an Assistant Professor of Medicine and Assistant Director of the McDonnell Genome Institute at Washington University School of Medicine. Dr Griffith has extensive experience in the fields of genomics, bioinformatics, data mining, and cancer research. His research is focused on improving the understanding of cancer biology and the development of personalized medicine strategies for cancer using genomics and informatics technologies. The Griffith lab develops bioinformatics and statistical methods for the analysis of high throughput sequence data and identification of biomarkers for diagnostic, prognostic and drug response prediction. The Griffith lab uses CIViC to interpret variants identified in cases examined by the WASHU Genomics Tumor Board. He is a co-creator of the CIViC resource." #> #> $content[[5]]$user$country #> $content[[5]]$user$country$id #> [1] 214 #> #> $content[[5]]$user$country$iso #> [1] "US" #> #> $content[[5]]$user$country$name #> [1] "United States" #> #> #> $content[[5]]$user$featured_expert #> [1] TRUE #> #> $content[[5]]$user$accepted_license #> NULL #> #> $content[[5]]$user$signup_complete #> NULL #> #> $content[[5]]$user$affiliation #> [1] "" #> #> $content[[5]]$user$organization #> $content[[5]]$user$organization$id #> [1] 1 #> #> $content[[5]]$user$organization$name #> [1] "The McDonnell Genome Institute" #> #> $content[[5]]$user$organization$url #> [1] "http://genome.wustl.edu/" #> #> $content[[5]]$user$organization$description #> [1] "The McDonnell Genome Institute (MGI) is a world leader in the fast-paced, constantly changing field of genomics. A truly unique institution, we are pushing the limits of academic research by creating, testing, and implementing new approaches to the study of biology with the goal of understanding human health and disease, as well as evolution and the biology of other organisms." #> #> $content[[5]]$user$organization$profile_image #> $content[[5]]$user$organization$profile_image$x256 #> [1] "/system/organizations/profile_images/000/000/001/x256/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[5]]$user$organization$profile_image$x128 #> [1] "/system/organizations/profile_images/000/000/001/x128/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[5]]$user$organization$profile_image$x64 #> [1] "/system/organizations/profile_images/000/000/001/x64/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[5]]$user$organization$profile_image$x32 #> [1] "/system/organizations/profile_images/000/000/001/x32/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[5]]$user$organization$profile_image$x14 #> [1] "/system/organizations/profile_images/000/000/001/x14/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> #> $content[[5]]$user$organization$parent #> named list() #> #> #> #> $content[[5]]$created_at #> [1] "2015-11-10T19:49:21.843Z" #> #> $content[[5]]$changes #> $content[[5]]$changes$chromosome #> $content[[5]]$changes$chromosome[[1]] #> NULL #> #> $content[[5]]$changes$chromosome[[2]] #> [1] "22" #> #> #> $content[[5]]$changes$start #> $content[[5]]$changes$start[[1]] #> NULL #> #> $content[[5]]$changes$start[[2]] #> [1] "23522397" #> #> #> $content[[5]]$changes$stop #> $content[[5]]$changes$stop[[1]] #> NULL #> #> $content[[5]]$changes$stop[[2]] #> [1] "23632600" #> #> #> $content[[5]]$changes$representative_transcript #> $content[[5]]$changes$representative_transcript[[1]] #> NULL #> #> $content[[5]]$changes$representative_transcript[[2]] #> [1] "ENST00000305877.8 (v75)" #> #> #> $content[[5]]$changes$chromosome2 #> $content[[5]]$changes$chromosome2[[1]] #> NULL #> #> $content[[5]]$changes$chromosome2[[2]] #> [1] "9" #> #> #> $content[[5]]$changes$start2 #> $content[[5]]$changes$start2[[1]] #> NULL #> #> $content[[5]]$changes$start2[[2]] #> [1] "133729451" #> #> #> $content[[5]]$changes$stop2 #> $content[[5]]$changes$stop2[[1]] #> NULL #> #> $content[[5]]$changes$stop2[[2]] #> [1] "133763063" #> #> #> #> $content[[5]]$diffs #> $content[[5]]$diffs$chromosome #> $content[[5]]$diffs$chromosome$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>22</ins></li>\n </ul>\n</div>\n" #> #> $content[[5]]$diffs$chromosome$final #> [1] "22" #> #> #> $content[[5]]$diffs$start #> $content[[5]]$diffs$start$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>23522397</ins></li>\n </ul>\n</div>\n" #> #> $content[[5]]$diffs$start$final #> [1] "23522397" #> #> #> $content[[5]]$diffs$stop #> $content[[5]]$diffs$stop$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>23632600</ins></li>\n </ul>\n</div>\n" #> #> $content[[5]]$diffs$stop$final #> [1] "23632600" #> #> #> $content[[5]]$diffs$representative_transcript #> $content[[5]]$diffs$representative_transcript$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>ENST00000305877.8 (v75)</ins></li>\n </ul>\n</div>\n" #> #> $content[[5]]$diffs$representative_transcript$final #> [1] "ENST00000305877.8 (v75)" #> #> #> $content[[5]]$diffs$chromosome2 #> $content[[5]]$diffs$chromosome2$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>9</ins></li>\n </ul>\n</div>\n" #> #> $content[[5]]$diffs$chromosome2$final #> [1] "9" #> #> #> $content[[5]]$diffs$start2 #> $content[[5]]$diffs$start2$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>133729451</ins></li>\n </ul>\n</div>\n" #> #> $content[[5]]$diffs$start2$final #> [1] "133729451" #> #> #> $content[[5]]$diffs$stop2 #> $content[[5]]$diffs$stop2$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>133763063</ins></li>\n </ul>\n</div>\n" #> #> $content[[5]]$diffs$stop2$final #> [1] "133763063" #> #> #> #> #> $content[[6]] #> $content[[6]]$id #> [1] 2906 #> #> $content[[6]]$action #> [1] "update" #> #> $content[[6]]$user #> $content[[6]]$user$id #> [1] 6 #> #> $content[[6]]$user$name #> [1] "Kilannin Krysiak" #> #> $content[[6]]$user$last_seen_at #> [1] "2019-09-03T16:28:00.554Z" #> #> $content[[6]]$user$username #> [1] "kkrysiak" #> #> $content[[6]]$user$role #> [1] "admin" #> #> $content[[6]]$user$avatar_url #> [1] "https://secure.gravatar.com/avatar/17180f9afc9f7f04fff97197c1ee5cb6.png?d=identicon&r=pg&s=32" #> #> $content[[6]]$user$avatars #> $content[[6]]$user$avatars$x128 #> [1] "https://secure.gravatar.com/avatar/17180f9afc9f7f04fff97197c1ee5cb6.png?d=identicon&r=pg&s=128" #> #> $content[[6]]$user$avatars$x64 #> [1] "https://secure.gravatar.com/avatar/17180f9afc9f7f04fff97197c1ee5cb6.png?d=identicon&r=pg&s=64" #> #> $content[[6]]$user$avatars$x32 #> [1] "https://secure.gravatar.com/avatar/17180f9afc9f7f04fff97197c1ee5cb6.png?d=identicon&r=pg&s=32" #> #> $content[[6]]$user$avatars$x14 #> [1] "https://secure.gravatar.com/avatar/17180f9afc9f7f04fff97197c1ee5cb6.png?d=identicon&r=pg&s=14" #> #> #> $content[[6]]$user$area_of_expertise #> [1] "Research Scientist" #> #> $content[[6]]$user$orcid #> [1] "0000-0002-6299-9230" #> #> $content[[6]]$user$display_name #> [1] "kkrysiak" #> #> $content[[6]]$user$created_at #> [1] "2015-02-26T04:14:20.953Z" #> #> $content[[6]]$user$url #> [1] "" #> #> $content[[6]]$user$twitter_handle #> [1] "" #> #> $content[[6]]$user$facebook_profile #> [1] "" #> #> $content[[6]]$user$linkedin_profile #> [1] "kilannin-krysiak-69047819" #> #> $content[[6]]$user$bio #> [1] "Dr. Krysiak is an Instructor at the McDonnell Genome Institute at Washington University School of Medicine where she is involved in the comprehensive genomic analysis of cancer patient cohorts and “n-of-1” studies. She received her PhD in Molecular Genetics and Genomics at Washington University in St. Louis where she focused on the genetics of myelodysplastic syndrome through advanced flow cytometry techniques, primary cell culture and mouse models. She is a founding member of the CIViC team, helping to define the CIViC data model, and a leading content curator and feature development consultant." #> #> $content[[6]]$user$country #> $content[[6]]$user$country$id #> [1] 214 #> #> $content[[6]]$user$country$iso #> [1] "US" #> #> $content[[6]]$user$country$name #> [1] "United States" #> #> #> $content[[6]]$user$featured_expert #> [1] TRUE #> #> $content[[6]]$user$accepted_license #> NULL #> #> $content[[6]]$user$signup_complete #> NULL #> #> $content[[6]]$user$affiliation #> [1] "" #> #> $content[[6]]$user$organization #> $content[[6]]$user$organization$id #> [1] 1 #> #> $content[[6]]$user$organization$name #> [1] "The McDonnell Genome Institute" #> #> $content[[6]]$user$organization$url #> [1] "http://genome.wustl.edu/" #> #> $content[[6]]$user$organization$description #> [1] "The McDonnell Genome Institute (MGI) is a world leader in the fast-paced, constantly changing field of genomics. A truly unique institution, we are pushing the limits of academic research by creating, testing, and implementing new approaches to the study of biology with the goal of understanding human health and disease, as well as evolution and the biology of other organisms." #> #> $content[[6]]$user$organization$profile_image #> $content[[6]]$user$organization$profile_image$x256 #> [1] "/system/organizations/profile_images/000/000/001/x256/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[6]]$user$organization$profile_image$x128 #> [1] "/system/organizations/profile_images/000/000/001/x128/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[6]]$user$organization$profile_image$x64 #> [1] "/system/organizations/profile_images/000/000/001/x64/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[6]]$user$organization$profile_image$x32 #> [1] "/system/organizations/profile_images/000/000/001/x32/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[6]]$user$organization$profile_image$x14 #> [1] "/system/organizations/profile_images/000/000/001/x14/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> #> $content[[6]]$user$organization$parent #> named list() #> #> #> #> $content[[6]]$created_at #> [1] "2015-12-02T19:39:00.778Z" #> #> $content[[6]]$changes #> $content[[6]]$changes$description #> $content[[6]]$changes$description[[1]] #> [1] "The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is the most well-studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). But despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and ponatinib) have seen some success in delivering a tumor response." #> #> $content[[6]]$changes$description[[2]] #> [1] "The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and ponatinib) have seen some success in delivering a tumor response." #> #> #> #> $content[[6]]$diffs #> $content[[6]]$diffs$description #> $content[[6]]$diffs$description$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"del\"><del>The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is the most <strong>well-</strong>studied fusion gene in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). <strong>But</strong> despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and ponatinib) have seen some success in delivering a tumor response.</del></li>\n <li class=\"ins\"><ins>The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is <strong>one of </strong>the most studied fusion gene<strong>s</strong> in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). <strong>However,</strong> despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and ponatinib) have seen some success in delivering a tumor response.</ins></li>\n </ul>\n</div>\n" #> #> $content[[6]]$diffs$description$final #> [1] "The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and ponatinib) have seen some success in delivering a tumor response." #> #> #> #> #> $content[[7]] #> $content[[7]]$id #> [1] 4232 #> #> $content[[7]]$action #> [1] "update" #> #> $content[[7]]$user #> $content[[7]]$user$username #> [1] "Admin" #> #> #> $content[[7]]$created_at #> [1] "2016-01-22T19:40:49.335Z" #> #> $content[[7]]$changes #> $content[[7]]$changes$representative_transcript #> $content[[7]]$changes$representative_transcript[[1]] #> [1] "ENST00000305877.8 (v75)" #> #> $content[[7]]$changes$representative_transcript[[2]] #> [1] "ENST00000305877.8" #> #> #> $content[[7]]$changes$ensembl_version #> $content[[7]]$changes$ensembl_version[[1]] #> NULL #> #> $content[[7]]$changes$ensembl_version[[2]] #> [1] 75 #> #> #> #> $content[[7]]$diffs #> $content[[7]]$diffs$representative_transcript #> $content[[7]]$diffs$representative_transcript$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"del\"><del>ENST00000305877.8<strong> (v75)</strong></del></li>\n <li class=\"ins\"><ins>ENST00000305877.8</ins></li>\n </ul>\n</div>\n" #> #> $content[[7]]$diffs$representative_transcript$final #> [1] "ENST00000305877.8" #> #> #> $content[[7]]$diffs$ensembl_version #> $content[[7]]$diffs$ensembl_version$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>75</ins></li>\n </ul>\n</div>\n" #> #> $content[[7]]$diffs$ensembl_version$final #> [1] 75 #> #> #> #> #> $content[[8]] #> $content[[8]]$id #> [1] 7140 #> #> $content[[8]]$action #> [1] "update" #> #> $content[[8]]$user #> $content[[8]]$user$id #> [1] 3 #> #> $content[[8]]$user$name #> [1] "Obi Griffith" #> #> $content[[8]]$user$last_seen_at #> [1] "2019-08-26T20:34:15.034Z" #> #> $content[[8]]$user$username #> [1] "obigriffith" #> #> $content[[8]]$user$role #> [1] "admin" #> #> $content[[8]]$user$avatar_url #> [1] "https://secure.gravatar.com/avatar/4c468e9a95d6135e02eb66ee5f2fb574.png?d=identicon&r=pg&s=32" #> #> $content[[8]]$user$avatars #> $content[[8]]$user$avatars$x128 #> [1] "https://secure.gravatar.com/avatar/4c468e9a95d6135e02eb66ee5f2fb574.png?d=identicon&r=pg&s=128" #> #> $content[[8]]$user$avatars$x64 #> [1] "https://secure.gravatar.com/avatar/4c468e9a95d6135e02eb66ee5f2fb574.png?d=identicon&r=pg&s=64" #> #> $content[[8]]$user$avatars$x32 #> [1] "https://secure.gravatar.com/avatar/4c468e9a95d6135e02eb66ee5f2fb574.png?d=identicon&r=pg&s=32" #> #> $content[[8]]$user$avatars$x14 #> [1] "https://secure.gravatar.com/avatar/4c468e9a95d6135e02eb66ee5f2fb574.png?d=identicon&r=pg&s=14" #> #> #> $content[[8]]$user$area_of_expertise #> [1] "Research Scientist" #> #> $content[[8]]$user$orcid #> [1] "0000-0002-0843-4271" #> #> $content[[8]]$user$display_name #> [1] "obigriffith" #> #> $content[[8]]$user$created_at #> [1] "2015-02-26T02:53:49.147Z" #> #> $content[[8]]$user$url #> [1] "http://genome.wustl.edu/people/individual/obi-griffith/" #> #> $content[[8]]$user$twitter_handle #> [1] "obigriffith" #> #> $content[[8]]$user$facebook_profile #> [1] "" #> #> $content[[8]]$user$linkedin_profile #> [1] "obigriffith" #> #> $content[[8]]$user$bio #> [1] "Dr. Griffith is Assistant Professor of Medicine and Assistant Director of the McDonnell Genome Institute at Washington University School of Medicine. He has worked in genomics and bioinformatics since the earliest phase of reference genome sequencing. He contributed to the Mammalian Gene Collection, producing some of the first full-length sequences for many human genes. He also was part of a small team of bioinformaticians that helped sequence and release the first whole genome reference sequence for the severe acute respiratory syndrome (SARS) virus at the height of the 2003 epidemic. He has contributed to the identification of molecular markers at the DNA, RNA and protein level that are useful for diagnosis and prognosis of thyroid, breast, lymphoma and other cancers. His lab’s research is focused on the development of informatics resources and personalized medicine strategies for cancer using genomic technologies. He is a co-creator of the CIViC resource." #> #> $content[[8]]$user$country #> $content[[8]]$user$country$id #> [1] 214 #> #> $content[[8]]$user$country$iso #> [1] "US" #> #> $content[[8]]$user$country$name #> [1] "United States" #> #> #> $content[[8]]$user$featured_expert #> [1] TRUE #> #> $content[[8]]$user$accepted_license #> NULL #> #> $content[[8]]$user$signup_complete #> NULL #> #> $content[[8]]$user$affiliation #> [1] "" #> #> $content[[8]]$user$organization #> $content[[8]]$user$organization$id #> [1] 1 #> #> $content[[8]]$user$organization$name #> [1] "The McDonnell Genome Institute" #> #> $content[[8]]$user$organization$url #> [1] "http://genome.wustl.edu/" #> #> $content[[8]]$user$organization$description #> [1] "The McDonnell Genome Institute (MGI) is a world leader in the fast-paced, constantly changing field of genomics. A truly unique institution, we are pushing the limits of academic research by creating, testing, and implementing new approaches to the study of biology with the goal of understanding human health and disease, as well as evolution and the biology of other organisms." #> #> $content[[8]]$user$organization$profile_image #> $content[[8]]$user$organization$profile_image$x256 #> [1] "/system/organizations/profile_images/000/000/001/x256/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[8]]$user$organization$profile_image$x128 #> [1] "/system/organizations/profile_images/000/000/001/x128/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[8]]$user$organization$profile_image$x64 #> [1] "/system/organizations/profile_images/000/000/001/x64/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[8]]$user$organization$profile_image$x32 #> [1] "/system/organizations/profile_images/000/000/001/x32/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[8]]$user$organization$profile_image$x14 #> [1] "/system/organizations/profile_images/000/000/001/x14/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> #> $content[[8]]$user$organization$parent #> named list() #> #> #> #> $content[[8]]$created_at #> [1] "2016-03-02T22:51:22.003Z" #> #> $content[[8]]$changes #> $content[[8]]$changes$representative_transcript2 #> $content[[8]]$changes$representative_transcript2[[1]] #> NULL #> #> $content[[8]]$changes$representative_transcript2[[2]] #> [1] "ENST00000372348.2" #> #> #> #> $content[[8]]$diffs #> $content[[8]]$diffs$representative_transcript2 #> $content[[8]]$diffs$representative_transcript2$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>ENST00000372348.2</ins></li>\n </ul>\n</div>\n" #> #> $content[[8]]$diffs$representative_transcript2$final #> [1] "ENST00000372348.2" #> #> #> #> #> $content[[9]] #> $content[[9]]$id #> [1] 7214 #> #> $content[[9]]$action #> [1] "update" #> #> $content[[9]]$user #> $content[[9]]$user$id #> [1] 15 #> #> $content[[9]]$user$name #> [1] "Malachi Griffith" #> #> $content[[9]]$user$last_seen_at #> [1] "2019-08-29T20:56:30.703Z" #> #> $content[[9]]$user$username #> [1] "MalachiGriffith" #> #> $content[[9]]$user$role #> [1] "admin" #> #> $content[[9]]$user$avatar_url #> [1] "https://secure.gravatar.com/avatar/a4d9fc3b05d58cf3d3ba51dc30bb61d6.png?d=identicon&r=pg&s=32" #> #> $content[[9]]$user$avatars #> $content[[9]]$user$avatars$x128 #> [1] "https://secure.gravatar.com/avatar/a4d9fc3b05d58cf3d3ba51dc30bb61d6.png?d=identicon&r=pg&s=128" #> #> $content[[9]]$user$avatars$x64 #> [1] "https://secure.gravatar.com/avatar/a4d9fc3b05d58cf3d3ba51dc30bb61d6.png?d=identicon&r=pg&s=64" #> #> $content[[9]]$user$avatars$x32 #> [1] "https://secure.gravatar.com/avatar/a4d9fc3b05d58cf3d3ba51dc30bb61d6.png?d=identicon&r=pg&s=32" #> #> $content[[9]]$user$avatars$x14 #> [1] "https://secure.gravatar.com/avatar/a4d9fc3b05d58cf3d3ba51dc30bb61d6.png?d=identicon&r=pg&s=14" #> #> #> $content[[9]]$user$area_of_expertise #> [1] "Research Scientist" #> #> $content[[9]]$user$orcid #> [1] "0000-0002-6388-446X" #> #> $content[[9]]$user$display_name #> [1] "MalachiGriffith" #> #> $content[[9]]$user$created_at #> [1] "2015-02-26T22:25:34.692Z" #> #> $content[[9]]$user$url #> [1] "http://genome.wustl.edu/people/individual/malachi-griffith/" #> #> $content[[9]]$user$twitter_handle #> [1] "malachigriffith" #> #> $content[[9]]$user$facebook_profile #> [1] "" #> #> $content[[9]]$user$linkedin_profile #> [1] "malachigriffith" #> #> $content[[9]]$user$bio #> [1] "Dr. Griffith is an Assistant Professor of Medicine and Assistant Director of the McDonnell Genome Institute at Washington University School of Medicine. Dr Griffith has extensive experience in the fields of genomics, bioinformatics, data mining, and cancer research. His research is focused on improving the understanding of cancer biology and the development of personalized medicine strategies for cancer using genomics and informatics technologies. The Griffith lab develops bioinformatics and statistical methods for the analysis of high throughput sequence data and identification of biomarkers for diagnostic, prognostic and drug response prediction. The Griffith lab uses CIViC to interpret variants identified in cases examined by the WASHU Genomics Tumor Board. He is a co-creator of the CIViC resource." #> #> $content[[9]]$user$country #> $content[[9]]$user$country$id #> [1] 214 #> #> $content[[9]]$user$country$iso #> [1] "US" #> #> $content[[9]]$user$country$name #> [1] "United States" #> #> #> $content[[9]]$user$featured_expert #> [1] TRUE #> #> $content[[9]]$user$accepted_license #> NULL #> #> $content[[9]]$user$signup_complete #> NULL #> #> $content[[9]]$user$affiliation #> [1] "" #> #> $content[[9]]$user$organization #> $content[[9]]$user$organization$id #> [1] 1 #> #> $content[[9]]$user$organization$name #> [1] "The McDonnell Genome Institute" #> #> $content[[9]]$user$organization$url #> [1] "http://genome.wustl.edu/" #> #> $content[[9]]$user$organization$description #> [1] "The McDonnell Genome Institute (MGI) is a world leader in the fast-paced, constantly changing field of genomics. A truly unique institution, we are pushing the limits of academic research by creating, testing, and implementing new approaches to the study of biology with the goal of understanding human health and disease, as well as evolution and the biology of other organisms." #> #> $content[[9]]$user$organization$profile_image #> $content[[9]]$user$organization$profile_image$x256 #> [1] "/system/organizations/profile_images/000/000/001/x256/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[9]]$user$organization$profile_image$x128 #> [1] "/system/organizations/profile_images/000/000/001/x128/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[9]]$user$organization$profile_image$x64 #> [1] "/system/organizations/profile_images/000/000/001/x64/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[9]]$user$organization$profile_image$x32 #> [1] "/system/organizations/profile_images/000/000/001/x32/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[9]]$user$organization$profile_image$x14 #> [1] "/system/organizations/profile_images/000/000/001/x14/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> #> $content[[9]]$user$organization$parent #> named list() #> #> #> #> $content[[9]]$created_at #> [1] "2016-03-08T23:24:25.310Z" #> #> $content[[9]]$changes #> $content[[9]]$changes$representative_transcript2 #> $content[[9]]$changes$representative_transcript2[[1]] #> [1] "ENST00000372348.2" #> #> $content[[9]]$changes$representative_transcript2[[2]] #> [1] "ENST00000318560.5" #> #> #> #> $content[[9]]$diffs #> $content[[9]]$diffs$representative_transcript2 #> $content[[9]]$diffs$representative_transcript2$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"del\"><del>ENST000003<strong>72348.2</strong></del></li>\n <li class=\"ins\"><ins>ENST000003<strong>18560.5</strong></ins></li>\n </ul>\n</div>\n" #> #> $content[[9]]$diffs$representative_transcript2$final #> [1] "ENST00000318560.5" #> #> #> #> #> $content[[10]] #> $content[[10]]$id #> [1] 61431 #> #> $content[[10]]$action #> [1] "update" #> #> $content[[10]]$user #> $content[[10]]$user$id #> [1] 41 #> #> $content[[10]]$user$name #> [1] "Nick Spies" #> #> $content[[10]]$user$last_seen_at #> [1] "2019-01-20T03:51:36.969Z" #> #> $content[[10]]$user$username #> [1] "NickSpies" #> #> $content[[10]]$user$role #> [1] "admin" #> #> $content[[10]]$user$avatar_url #> [1] "https://secure.gravatar.com/avatar/3376aeb8439c5ab3e5d72fa2eeed39e5.png?d=identicon&r=pg&s=32" #> #> $content[[10]]$user$avatars #> $content[[10]]$user$avatars$x128 #> [1] "https://secure.gravatar.com/avatar/3376aeb8439c5ab3e5d72fa2eeed39e5.png?d=identicon&r=pg&s=128" #> #> $content[[10]]$user$avatars$x64 #> [1] "https://secure.gravatar.com/avatar/3376aeb8439c5ab3e5d72fa2eeed39e5.png?d=identicon&r=pg&s=64" #> #> $content[[10]]$user$avatars$x32 #> [1] "https://secure.gravatar.com/avatar/3376aeb8439c5ab3e5d72fa2eeed39e5.png?d=identicon&r=pg&s=32" #> #> $content[[10]]$user$avatars$x14 #> [1] "https://secure.gravatar.com/avatar/3376aeb8439c5ab3e5d72fa2eeed39e5.png?d=identicon&r=pg&s=14" #> #> #> $content[[10]]$user$area_of_expertise #> [1] "Research Scientist" #> #> $content[[10]]$user$orcid #> [1] "" #> #> $content[[10]]$user$display_name #> [1] "NickSpies" #> #> $content[[10]]$user$created_at #> [1] "2015-06-12T18:13:16.508Z" #> #> $content[[10]]$user$url #> [1] "" #> #> $content[[10]]$user$twitter_handle #> [1] "@NickSpies13" #> #> $content[[10]]$user$facebook_profile #> [1] "" #> #> $content[[10]]$user$linkedin_profile #> [1] "" #> #> $content[[10]]$user$bio #> [1] "Nick Spies is a staff analyst at the McDonnell Genome Institute and an MD student at Washington University School of Medicine. He has made substantial contributions to the development of genome analysis tools and resources at the Genome Institute including the Drug-Gene Interaction Database. He is a founding member of the CIViC team, helping to define the CIViC data model, and a leading content curator and a feature development consultant." #> #> $content[[10]]$user$country #> $content[[10]]$user$country$id #> [1] 214 #> #> $content[[10]]$user$country$iso #> [1] "US" #> #> $content[[10]]$user$country$name #> [1] "United States" #> #> #> $content[[10]]$user$featured_expert #> [1] TRUE #> #> $content[[10]]$user$accepted_license #> NULL #> #> $content[[10]]$user$signup_complete #> NULL #> #> $content[[10]]$user$affiliation #> [1] "" #> #> $content[[10]]$user$organization #> $content[[10]]$user$organization$id #> [1] 1 #> #> $content[[10]]$user$organization$name #> [1] "The McDonnell Genome Institute" #> #> $content[[10]]$user$organization$url #> [1] "http://genome.wustl.edu/" #> #> $content[[10]]$user$organization$description #> [1] "The McDonnell Genome Institute (MGI) is a world leader in the fast-paced, constantly changing field of genomics. A truly unique institution, we are pushing the limits of academic research by creating, testing, and implementing new approaches to the study of biology with the goal of understanding human health and disease, as well as evolution and the biology of other organisms." #> #> $content[[10]]$user$organization$profile_image #> $content[[10]]$user$organization$profile_image$x256 #> [1] "/system/organizations/profile_images/000/000/001/x256/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[10]]$user$organization$profile_image$x128 #> [1] "/system/organizations/profile_images/000/000/001/x128/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[10]]$user$organization$profile_image$x64 #> [1] "/system/organizations/profile_images/000/000/001/x64/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[10]]$user$organization$profile_image$x32 #> [1] "/system/organizations/profile_images/000/000/001/x32/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> $content[[10]]$user$organization$profile_image$x14 #> [1] "/system/organizations/profile_images/000/000/001/x14/MGI_STANDARD4_logo_brown-example_v1b.png?1494525976" #> #> #> $content[[10]]$user$organization$parent #> named list() #> #> #> #> $content[[10]]$created_at #> [1] "2017-06-12T15:39:18.352Z" #> #> $content[[10]]$changes #> $content[[10]]$changes$description #> $content[[10]]$changes$description[[1]] #> [1] "The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and ponatinib) have seen some success in delivering a tumor response." #> #> $content[[10]]$changes$description[[2]] #> [1] "The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors." #> #> #> #> $content[[10]]$diffs #> $content[[10]]$diffs$description #> $content[[10]]$diffs$description$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"del\"><del>The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and <strong>pona</strong>tinib) have seen some success in delivering a tumor response.</del></li>\n <li class=\"ins\"><ins>The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and <strong>nilo</strong>tinib) have seen some success in delivering a tumor response.<strong> Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.</strong></ins></li>\n </ul>\n</div>\n" #> #> $content[[10]]$diffs$description$final #> [1] "The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors." #> #> #> #> #> $content[[11]] #> $content[[11]]$id #> [1] 67279 #> #> $content[[11]]$action #> [1] "update" #> #> $content[[11]]$user #> $content[[11]]$user$username #> [1] "Admin" #> #> #> $content[[11]]$created_at #> [1] "2017-12-01T14:40:28.542Z" #> #> $content[[11]]$changes #> $content[[11]]$changes$civic_actionability_score #> $content[[11]]$changes$civic_actionability_score[[1]] #> NULL #> #> $content[[11]]$changes$civic_actionability_score[[2]] #> [1] 238 #> #> #> #> $content[[11]]$diffs #> $content[[11]]$diffs$civic_actionability_score #> $content[[11]]$diffs$civic_actionability_score$diff #> [1] "<div class=\"diff\">\n <ul>\n <li class=\"ins\"><ins>238.0</ins></li>\n </ul>\n</div>\n" #> #> $content[[11]]$diffs$civic_actionability_score$final #> [1] 238 #> #> #> #> #> #> $url #> [1] "https://civicdb.org/api/variants/1/revisions" #> #> $response #> Response [https://civicdb.org/api/variants/1/revisions] #> Date: 2019-09-03 16:44 #> Status: 200 #> Content-Type: application/json; charset=utf-8 #> Size: 47.4 kB #> #> #> attr(,"class") #> [1] "civic_api"